Skip to Content

Join the 'Tacrolimus' group to help and get support from people like you.

Tacrolimus News

Related terms: Tacrolimus Topical

Study Suggests Causes for Lupus' Impact on Immune System

Posted 8 Mar 2016 by Drugs.com

TUESDAY, March 8, 2016 – Scientists have found new clues that help explain what's going wrong in the immune systems of people with lupus – insight they hope will lead to new therapies, or help guide current treatment choices. Lupus has several forms, but the most common is systemic lupus erythematosus (SLE). In SLE, the immune system mistakenly produces antibodies against the body's own tissue. The onslaught can have widespread effects, damaging the skin, joints, heart, lungs, kidneys and brain, according to the Lupus Foundation of America. The disease mostly strikes women, usually starting in their 20s or 30s, the foundation says. In the new study, the researchers found evidence that in people with lupus, some of the immune system's "B cells" mature the wrong way – so that they promote inflammation instead of fighting it. The findings, published online March 8 in the journal ... Read more

Related support groups: Systemic Lupus Erythematosus, Plaquenil, Hydroxychloroquine, Rituxan, Prograf, Rituximab, Tacrolimus, Lupus Erythematosus, Cytoxan, Protopic, Cyclophosphamide, Envarsus XR, Cytoxan Lyophilized, Quineprox, Astagraf XL, Neosar, Plaquenil Sulfate, Hecoria

FDA Approves Envarsus XR (tacrolimus) for Prevention of Organ Rejection in Kidney Transplant Patients

Posted 24 Jul 2015 by Drugs.com

Hørsholm, Denmark, July 10, 2015 – Veloxis Pharmaceuticals A/S (OMX: VELO) today announced U.S. Food and Drug Administration (FDA) approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR. Veloxis expects Envarsus XR to be available to patients in the United States and their physicians in 4Q 2015. Envarsus XR is an extended release formulation of tacrolimus designed for once-daily dosing, with flatter pharmacokinetics and greater bioavailability compared to twice-daily tacrolimus. The FDA marketing approval is based on the review of two Phase III trials and several Phase II trials in kidney transplant recipients. In all of the clinical trials, Envarsus XR dosed once daily demonstrated significantly higher ... Read more

Related support groups: Tacrolimus, Envarsus XR, Rejection Prophylaxis

New Technique Protects Tissue Transplant From Rejection: Study

Posted 13 Aug 2014 by Drugs.com

WEDNESDAY, Aug. 13, 2014 – A new technique for delivering anti-rejection drugs directly to the site of a tissue graft transplant is effective, lasts for months and is safer than drugs that suppress the entire immune system, a new study indicates. After a patient receives a tissue graft transplant – typically on the hand, arm, leg or face – they start taking drugs to prevent their immune system from rejecting and attacking the new tissue. However, this approach can be toxic and leave patients vulnerable to infection. The new approach delivers immunosuppressant drugs directly to the site of the tissue graft transplant, and only when they're needed. A hydrogel (jello-like) material is loaded with an immunosuppressant drug called tacrolimus, and this combination is injected under the skin after transplant surgery. The hydrogel remains inactive until it detects an inflammation/immune ... Read more

Related support groups: Prograf, Tacrolimus, Organ Transplant, Hecoria

Astellas Announces FDA Approval of Astagraf XL (tacrolimus extended-release capsules) for the Prophylaxis of Organ Rejection

Posted 22 Jul 2013 by Drugs.com

NORTHBROOK, Ill., July 19, 2013 /PRNewswire/ – Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Astagraf XL (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. "Each transplant recipient is different and requires a personalized treatment approach. The approval of Astagraf XL marks an important milestone in post-transplant care as it provides physicians with a new treatment option for kidney transplant recipients," said Sef Kurstjens, M.D., PhD., chief medical officer, Astellas Pharma, Inc. "Astellas is pleased to continue our more than 20-year commitment to the field of transplant immunology." Astagraf XL ... Read more

Related support groups: Tacrolimus, Organ Transplant - Rejection Prophylaxis

Ask a Question

Further Information

Related Condition Support Groups

Organ Transplant - Rejection Reversal, Organ Transplant - Rejection Prophylaxis, Graft-versus-host disease, Crohn's Disease

Related Drug Support Groups

Prograf, Envarsus XR, Astagraf XL, Hecoria

Tacrolimus Patient Information at Drugs.com